AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12701337
Drug: Conventional CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional CPAP treatment (n = 50)
Trial: 9557050
Drug: Mucosolvan (mucolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosolvan (mucolytic preparation)
Trial: 1304021
Drug: Spiramycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiramycin (1 gram twice daily)
Trial: 1304021
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg thrice or four times daily)
Trial: 27010957
Drug: Omalizumab 300
RxNorm normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 300 mg every 4 weeks up to week 24
Trial: 24296715
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor antagonist (exendin-9)
Trial: 26076755
Drug: Contextual Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contextual Cognitive Behavioural Therapy (CCBT)
Trial: 23764140
Drug: Treatment As
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment As Usual (TAU) physiotherapy
Trial: 16374158
Drug: Short-stay intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-stay intensive care (SSIC) treatment (8 hrs of intensive care treatment)
Trial: 14635284
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg twice a day of celecoxib
Trial: 14635284
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg twice a day of celecoxib
Trial: 14635284
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg twice a day of celecoxib
Trial: 14635284
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg twice a day of naproxen
Trial: 3899029
Drug: Immunotherapy (Levamisole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (Levamisole and Intrapleural BCG)
Trial: 3899029
Drug: Chemotherapy (CisPlatinum,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CisPlatinum, Adriamycin, and Cytoxan)
Trial: 27871565
Drug: Periarticular drug
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular drug injection
Trial: 29121334
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dronabinol
Trial: 16710114
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg dronabinol
Trial: 22511794
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate infusion in thyroidectomized patients
Trial: 22511794
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate infusion in healthy volunteers
Trial: 20122281
Drug: Supervised, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised, twice weekly exercise training with regular review of airway clearance therapy
Trial: 20122281
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly telephone support
Trial: 15753114
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of aspirin on alternate days
Trial: 12897285
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose indomethacin (0.2 mg/kg/dose every 12 hours for 3 doses)
Trial: 12897285
Drug: Prolonged low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prolonged low-dose indomethacin (0.1 mg/kg/dose daily for 6 doses)
Trial: 12897285
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose indomethacin
Trial: 12897285
Drug: Prolonged low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prolonged low-dose indomethacin
Trial: 1851339
Drug: VACE regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VACE regimen (vincristine 1.2 mg/m2, doxorubicin 40 mg/m2, cyclophosphamide 700 mg/m2 on day 1 plus etoposide 110 mg/m2 daily for three days)
Trial: 1851339
Drug: CVACE regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVACE regimen (identical to VACE for cycles 3 and 4; cycles 1, 2, 4, and 6 consisted of etoposide 110 mg/m2 for three days plus cisplatin 100 mg/m2 with mannitol diuresis on the second day)
Trial: 6119097
Drug: Cloxazolam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloxazolam (3 mg)
Trial: 18762476
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (100 mg daily)
Trial: 31550962
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) plus low dose aspirin (40 mg enoxaparin and 100 mg aspirin daily)
Trial: 31550962
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) alone (40 mg enoxaparin daily)
Trial: 11309635
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg or 120 mg)
Trial: 8557525
Drug: Isoniazid tablets
RxNorm normalized name: Isoniazid Tablets
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid tablets plus pyridoxin tablets once a day for 30 days
Trial: 2796626
Drug: Intravenous lidocaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine, 1 mg/kg
Trial: 31176632
Drug: AP‐CD/LD (50/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP‐CD/LD (50/250 mg, 50/375 mg, or 50/500 mg)
Trial: 27986606
Drug: S-ketamine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (bolus of 0.11mg/kg, followed by a maintenance infusion of 0.12mg/kg)
Trial: 7988776
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NaCl infusion)
Trial: 24913571
Drug: Erythropoietin (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (total dose of about 40,000 U)
Trial: 22386829
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg and Amlodipine 10 mg (T/A)
Trial: 9066353
Drug: Cerebrospinal fluid/serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrospinal fluid/serum ratios for soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1
Trial: 9066353
Drug: Serum levels
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum levels for soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1
Trial: 8410217
Drug: Methylprednisolone (very
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (very high doses) administered within 8 hours of injury
Trial: 8410217
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment with methylprednisolone
Trial: 22500386
Drug: Danning Tablet
RxNorm normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danning Tablet
Trial: 20573778
Drug: Thiazide-like diuretic
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide-like diuretic (indapamide 1.5 mg SR) + ACE inhibitor (perindopril 2-4 mg)
Trial: 17646516
Drug: Intrathecal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal ropivacaine 2 mg
Trial: 17646516
Drug: Intrathecal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal ropivacaine 4 mg
Trial: 17646516
Drug: Intrathecal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal ropivacaine 7 mg
Trial: 17646516
Drug: Intrathecal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal ropivacaine 10 mg
Trial: 17646516
Drug: Intrathecal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal ropivacaine 14 mg
Trial: 17136950
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg daily for 6 weeks
Trial: 11995818
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy with six i.v. infusions of fotémustine
Trial: 10446490
Drug: KRN8602 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRN8602 (15 mg/m2/day for 5 days) + Cytosine arabinoside (100 mg/m2/day for 7 days)
Trial: 10446490
Drug: Daunorubicin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin (40 mg/m2/day for 3 days) + Cytosine arabinoside (100 mg/m2/day for 7 days)
Trial: 7493059
Drug: Oxygent® (1.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygent® (1.35 g PFC/kg)
Trial: 7493059
Drug: Oxygent® (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygent® (1.8 g PFC/kg)
Trial: 7471802
Drug: Halcinonide cream
RxNorm normalized name: Halcinonide Cream
DrugBank: Halcinonide (DB06786)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Halcinonide cream (0.025%)
Trial: 7471802
Drug: Halcinonide cream
RxNorm normalized name: Halcinonide Cream
DrugBank: Halcinonide (DB06786)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Halcinonide cream (0.025%) and Placebo cream
Trial: 31961926
Drug: Obinutuzumab-based chemotherapy
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab-based chemotherapy induction
Trial: 31961926
Drug: Rituximab-based chemotherapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab-based chemotherapy induction
Trial: 24576148
Drug: PSYMEPHY treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSYMEPHY treatment (6-week interdisciplinary treatment)
Trial: 22860637
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg AA
Trial: 22860637
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg AA
Trial: 22860637
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg AA
Trial: 17516992
Drug: CoQ(10) 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ(10) 100 mg, riboflavin 10 mg, niacin 50 mg along with tamoxifen 10 mg twice a day for 45 days (Group IV)
Trial: 17516992
Drug: CoQ(10) 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ(10) 100 mg, riboflavin 10 mg, niacin 50 mg along with tamoxifen 10 mg twice a day for 90 days (Group V)
Trial: 17516992
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg twice a day for more than 1 year (Group III)
Trial: 15498622
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg/d, at least one i.v. dose)
Trial: 11465936
Drug: alpha-tocopherol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-tocopherol (500 mg b.i.d.)
Trial: 2916871
Drug: Clonidine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (initial dose of 0.1 mg with hourly doses of 0.1 mg)
Trial: 30412905
Drug: Glucose (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (75 g, GLU) alone
Trial: 24725465
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with remifentanil and diclofenac (50 mg)
Trial: 24725465
Drug: Pethidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (2 mg/kg i.m.) and midazolam (7.5 mg)
Trial: 14596626
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive (Estrostep, containing norethisterone acetate 1mg and ethinylestradiol [20, 30, 35 mg])
Trial: 11024603
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (1 mg kg(‐1) bolus followed by 40 microg kg(‐1) min(‐1) for 4 hours)
Trial: 1307344
Drug: Conventional intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intramuscular analgesia
Trial: 29420518
Drug: Gabapentin 450
RxNorm normalized name: gabapentin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 450 mg
Trial: 22317944
Drug: Vitamins C
RxNorm normalized name: MULTIVITAMINS CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins C and E (200 mg and 400 mg respectively)
Trial: 22317944
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (200 mg) and placebo
Trial: 22317944
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 mg) and placebo
Trial: 20183736
Drug: Hypnosis/therapeutic suggestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis/therapeutic suggestion with standard sedation dose of intravenous anesthetic
Trial: 18568696
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment based on home BP monitoring
Trial: 12523216
Drug: Probiotics for
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics for systemic diseases (e.g., atopic dermatitis)
Trial: 6111330
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol 80 mg (single dose)
Trial: 6111330
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol 80 mg (2 weeks administration, twice daily)
Trial: 6111330
Drug: Intravenous propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propranolol (0.2 mg/kg)
Trial: 6111330
Drug: Intravenous practolol
RxNorm normalized name: practolol
DrugBank: Practolol (DB01297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous practolol (1 mg/kg)
Trial: 6111330
Drug: Intravenous atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atenolol (0.2 mg/kg)
Trial: 6111330
Drug: Intravenous SL
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous SL 75212 (0.15 and 0.6 mg/kg)
Trial: 6111330
Drug: Propranolol 100
RxNorm normalized name: propranolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 100 and 500 μg/ml added to whole blood
Trial: 6111330
Drug: Lignocaine 5
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 5 μg/ml added to whole blood
Trial: 6111330
Drug: Propranolol at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol at 1000 ng/ml or less
Trial: 6111330
Drug: Sotalol 5
RxNorm normalized name: SOTALOL 5MG/ML ORAL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 5 and 500 μg/ml and 5 mg/ml
Trial: 30793920
Drug: ¼ dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ¼ dose reduction fluoroscopy
Trial: 28202072
Drug: Mini implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini implants (MI)
Trial: 28202072
Drug: Conventional implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implants (CI)
Trial: 25823790
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg spironolactone (MR availability)
Trial: 19577021
Drug: Salbutamol (sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (sustained released formulation) administered orally at a daily dose of 16 mg using a periodic dosage regimen (3 wks on, 1 wk off)
Trial: 17038059
Drug: Oral-B CrossAction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B CrossAction Power (CAPB) with three different modes of brushing
Trial: 14642054
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment alone
Trial: 9308061
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion anaesthesia
Trial: 23318497
Drug: Exercise with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise with Acipimox (Aci) administration
Trial: 23318497
Drug: Acipimox (Aci)
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (Aci) administration post-exercise
Trial: 18259012
Drug: Norepinephrine transporter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine transporter inhibition with 8 mg reboxetine
Trial: 17020983
Drug: Paclitaxel alone
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel alone (175 mg/m(2)/i.v.)
Trial: 15284389
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein (S) - 26.6 +/- 4.5 g protein, 44.4 +/- 7.5 mg isoflavones/d
Trial: 15284389
Drug: Soy +
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy + probiotics (S+P) - 10(9) colony-forming units Lactobacillus acidophilus DDS+1 and Bifidobacterium longum, 15-30 mg fructooligosaccharide/d
Trial: 15284389
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein (M) - 26.6 +/- 4.5 g protein/d
Trial: 10197170
Drug: Synovial fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synovial fluid markers (aggrecan fragments, matrix metalloproteinases-1 and -3, tissue inhibitor of metalloproteinases-1)
Trial: 3277506
Drug: 4-aminosalicylic acid
RxNorm normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-aminosalicylic acid (2 g in 60 mL nightly retention enema for 8 weeks)
Trial: 3277506
Drug: Placebo (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (60 mL nightly retention enema for 8 weeks)
Trial: 28817199
Drug: Biological products
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological products for the treatment of rheumatoid arthritis
Trial: 26225130
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration (PLA)
Trial: 24188672
Drug: Immunotherapy (M-FP)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (M-FP)
Trial: 21344046
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention of CBT for insomnia and imagery rehearsal therapy
Trial: 21041921
Drug: etravirine 200
RxNorm normalized name: etravirine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etravirine 200 mg twice daily
Trial: 21150563
Drug: etravirine 400
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: etravirine 400 mg once daily
Trial: 18445705
Drug: moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moxifloxacin 400 mg once daily (positive control)
Trial: 16480472
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl (20 microg) added to hyperbaric bupivacaine (2.0 ml of 0.5%)
Trial: 16480472
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine (2.0 ml of 0.5%) with saline (0.4 ml)
Trial: 9093498
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy from a trained community nurse
Trial: 9093498
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual from general practitioner
Trial: 8458463
Drug: 7-day protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day protocol (Tripteriline 0.1, administered daily for 7 days starting on cycle day 2)
Trial: 8458463
Drug: Long protocol
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long protocol (Tripteriline 3.75 mg, administered on cycle day 2)
Trial: 2427857
Drug: Celiprolol (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (0.07 and 0.14 mg/kg)
Trial: 2427857
Drug: Propranolol (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.07 mg/kg)
Trial: 27502721
Drug: Full (unadjusted)
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full (unadjusted) dose of chemotherapy